GPC3-Targeting Antibody Selection for Liver Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma, such as sorafenib, have limited effectiveness and are associated with adverse reactions, and there is a lack of methods to determine the efficacy of GPC3-targeting therapeutic agents for individual patients.
Innovation Solution
A method is developed to measure the expression level of GPC3 in tumor cells from patient biological samples, determining the effectiveness of a GPC3-targeting therapeutic agent based on this level, allowing for personalized administration of a GPC3-targeting therapeutic agent, including anti-GPC3 antibodies with ADCC and CDC activity, to achieve improved therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GPC3-targeting therapeutic agent is administered to all hepatocellular carcinoma patients, then some patients may benefit from targeted therapy, but resources are wasted on patients who will not respond and adverse reactions still occur
Solution Approach 1:
The patent performs preliminary measurement of GPC3 expression levels in tumor cells before administering the GPC3-targeting therapeutic agent. This preliminary action identifies patients who are likely to respond to therapy, preventing unnecessary medication exposure in non-responders while ensuring reliable therapeutic efficacy in appropriate candidates.
2Productivity
If current chemotherapy agents like sorafenib are used, then some cancer growth inhibition is achieved, but the objective response rate remains low and adverse reactions occur
Solution Approach 1:
The patent changes the therapeutic parameter from non-specific chemotherapy (sorafenib) to GPC3-specific targeted therapy. By measuring GPC3 expression levels and selecting patients with high expression, the therapy achieves higher objective response rates while maintaining cancer growth inhibition, effectively changing the specificity parameter of the treatment approach.
3Reliability
If invasive treatment approaches are used to achieve curative results, then some patients achieve better outcomes, but the procedures are complex and carry higher risks
Solution Approach 1:
The patent replaces complex mechanical/invasive treatment procedures with a molecular-level targeted therapy approach. By using GPC3-specific antibodies that target cancer cells at the molecular level, the treatment achieves curative outcomes through biological specificity rather than mechanical intervention, reducing procedural complexity and associated risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate determination of the effectiveness of GPC3-targeting therapeutic agents, improving treatment efficacy and quality of life for patients by ensuring the agent is only administered to those who will benefit, thereby enhancing cancer treatment outcomes.
Implementation Method 1
anti-GPC3 antibodies with ADCC and CDC activity
Implementation Method 2
anti-GPC3 antibodies with ADCC and CDC activity
Data Source
AI summary
The present invention provides a method for determining the efficacy of a GPC3-targeting therapeutic agent for a liver cancer patient and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a GPC3-targeting therapeutic agent is effective when the expression level of GPC3 per tumor cell is a predetermined value, and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective.